Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries

Given the evolving treatment landscape in metastatic urothelial cancer, this study investigated physicians' approaches to treatment and platinum -based chemotherapy eligibility in real-world consulting patients. In accordance with European guidelines, patients received standard-of-care first-line platinum -based chemotherapy, while immune checkpoint inhibitor use was limited. Physicians' perceptions will evolve with newer guideline recommendations and increased therapy options. Introduction: The global treatment landscape for metastatic urothelial cancer (mUC) is evolving, with the recent approval of several new therapeutics. To enable informed treatment decisions, a need exists to understand both treatment patterns and how physicians determine platinum -based treatment eligibility status. This study investigated physicians' current approaches to first-line (1L) chemotherapy, treatment patterns, and assessment of platinum-based treatment eligibility of patients with mUC in real-world clinical practice. Patients and Methods: Data were derived from the Adelphi mUC Disease Specific Programme (TM), a large, independent, multinational, cross-sectional survey of physicians and their consulting patients with mUC presenting in a real -world clinical setting, conducted in France, Germany, Italy, Spain, and the United Kingdom between November 2020 and April 2021. Physicians completed record forms for their next 8 consecutively consulting patients (<= 3 1L, <= 2 second-line, and <= 3 third-line) with a physician-confirmed diagnosis of mUC, reporting data on demographics, clinical characteristics, eligibility for platinum-based chemotherapy, and treatments received. Results: Overall, 232 physicians provided data for 1922 patients. Renal function impairment (72%), Eastern Cooperative Oncology Group performance status (59%), and age (38%) were the most commonly reported criteria physicians used to determine eligibility for platinum-based chemotherapy. At 1L, 82% of patients received platinum-based chemotherapy (cisplatin, 51%; carboplatin, 31%) and 10% received immune checkpoint inhibitor (ICI) therapy. At second-line, 12% received platinum -based chemotherapy, 63% ICI therapy, and 21% non-platinum-based chemotherapy. At third-line, 4% received platinum -based chemotherapy, 41% best supportive care only, and 36% other non-platinum-based chemotherapy. Conclusions: The results of this real -world study indicate that in accordance with European guidelines, the majority of patients with mUC received standard-of-care 1L platinum-based chemotherapy and use of ICIs was limited. Future research should assess how physicians' perceptions toward determining platinum eligibility status evolve with newer guideline recommendations and the introduction of new therapy options for mUC.